A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy

Epilepsy and Behavior

Volumn 10, Issue 2, 2007, Pages 291-295

  Kim, Sook Hui ^a   Lee, Jin Wha ^a   Choi, Kyoung Gyu ^a   Chung, Hye Won ^a   Lee, Hyang Woon ^a  

^a Ewha Womans University School of Medicine   (South Korea)

Author keywords

Antiepileptic drugs; Bone formation; Bone metabolism; Bone mineral density; Bone resorption; Carbamazepine

Indexed keywords

ANTICONVULSIVE AGENT; CALCIUM; CARBAMAZEPINE; LAMOTRIGINE; LIVER ENZYME; OSTEOCALCIN; PARATHYROID HORMONE; VALPROIC ACID; VITAMIN D;

ADULT; AGE DISTRIBUTION; ARTICLE; BONE DENSITY; BONE METABOLISM; CALCANEUS; CLINICAL ARTICLE; CONTROLLED STUDY; EPILEPSY; FEMALE; HUMAN; KOREA; LONGITUDINAL STUDY; MALE; METABOLIC BONE DISEASE; MONOTHERAPY; OSSIFICATION; OSTEOLYSIS; PROSPECTIVE STUDY; SIDE EFFECT;

ADOLESCENT; ADULT; ANTICONVULSANTS; BIOLOGICAL MARKERS; BONE DENSITY; BONE DISEASES, METABOLIC; CALCITRIOL; CARBAMAZEPINE; EPILEPSY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARATHYROID HORMONE; TRIAZINES; VALPROIC ACID; VITAMIN D;

EID: 33947269764     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2006.11.007     Document Type: Article

References (40)

1. Sheth R.D. Bone health in epilepsy. Lancet Neurol 3 (2004) 516
2. Hahn T.J., Hendin B.A., Scharp C.R., and Haddad Jr. J.G. Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults. N Engl J Med 287 (1972) 900-904
3. Stamp T.C., Round J.M., Rowe D.J.F., and Haddad J.G. Plasma levels and therapeutic effect of 25-hydroxycholecalciferol in epileptic patients taking anticonvulsant drugs. Br Med J 4 (1972) 9-12
4. Bouillon R., Reynaert J., Claes J.H., Lissens W., and De Moor P. The effect of anticonvulsant therapy on serum levels of 25-hydroxy-vitamin D, calcium, and parathyroid hormone. J Clin Endocrinol Metab 41 (1975) 1130-1135
5. Skillen A.W., and Pierides A.M. Serum gamma glutamyl transferase and alkaline phosphatase activities in epileptics receiving anticonvulsant therapy. Clin Chem Acta 72 (1976) 245-251
6. O'Hare J.A., Duggan B., O'Driscoll D., and Callaghan N. Biochemical evidence for osteomalacia with carbamazepine therapy. Acta Neurol Scand 62 (1980) 282-286
7. Hoikka V., Savolainen K., Alhava E.M., et al. Osteomalacia in institutionalized epileptic patients on long-term anticonvulsant therapy. Acta Neurol Scand 64 (1981) 122-131
8. Davie M.W., Emberson C.E., Lawson D.E., et al. Low plasma 25-hydroxyvitamin D and serum calcium in institutionalized epileptic subjects: associated risk factors, consequences and response to treatment with vitamin D. Q J Med 52 (1983) 79-91
9. Weinstein R.S., Bryce G.F., Sappington L.J., King D.W., and Gallagher B.B. Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment. J Clin Endocrinol Metab 58 (1984) 1003-1009
10. Gough H., Goggin T., Bissessar A., et al. A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in out-patients with epilepsy. Q J Med 59 (1986) 569-577
11. Bogliun G., Beghi E., Crespi V., Delodovici L., and d'Amico P. Anticonvulsant drugs and bone metabolism. Acta Neurol Scand 74 (1986) 284-288
12. Valimaki M.J., Tiihonen M., Laitinen K., et al. Bone mineral density measured by dual-energy X-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J Bone Miner Res 9 (1994) 631-637
13. Chung S., and Ahn C. Effects of anti-epileptic drug therapy on bone mineral density in ambulatory epileptic children. Brain Dev 16 (1994) 382-385
14. Verrotti A., Greco R., Morgese G., and Chiarelli F. Increased bone turnover in epileptic patients treated with carbamazepine. Ann Neurol 47 (2000) 385-388
15. Sheth R.D., Wesolowski C.A., Jacob J.C., et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr 127 (1995) 256-262
16. Stephen L.J., Mclellan A.R., Harrison J.H., et al. Bone density and antiepileptic drugs: a case-controlled study. Seizure 8 (1999) 339-342
17. Sato Y., Kondo I., Ishida S., et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 57 (2001) 445-449
18. Pack A.M., Morrell M.J., Marcus R., et al. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol 57 (2005) 252-257
19. Andress D.L., Ozuna J., Tirschwell D., et al. Antiepileptic drug induced bone loss in young male patients who have seizures. Arch Neurol 59 (2002) 781-786
20. Kumandas S., Koklu E., Gumus H., et al. Effect of carbamazepine and valproic acid on bone mineral density, IGF-I and IGFBP-3. J Pediatr Endocrinol Metab 19 (2006) 529-534
21. Pluskiewicz W., and Nowakowska J. Bone status after long-term anticonvulsant therapy in epileptic patients: evaluation using quantitative ultrasound of calcaneus and phalanges. Ultrasound Med Biol 23 (1997) 553-558
22. Pedrera J.D., Canal M.L., Carvajal J., et al. Influence of vitamin D administration on bone ultrasound measurements in patients on anticonvulsant therapy. Eur J Clin Invest 30 (2000) 895-899
23. 3 on bone-mineral content in carbamazepine-treated epileptic patients. Acta Neurol Scand 68 (1983) 424-428
24. Guo C., Ronen G.M., and Atkinson S.A. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 42 (2001) 1141-1147
25. Vogel J.M., Wasnich R.D., and Ross P.D. The clinical relevance of calcaneus bone mineral measurements: a review. Bone Miner 5 (1988) 35-58
26. Hoikka V., Alhava E.M., Karjalainen P., et al. Carbamazepine and bone mineral metabolism. Acta Neurol Scand 70 (1984) 77-80
27. Bramswig S., Zittermann A., and Berthold H.K. Carbamazepine does not alter biochemical parameters of bone turnover in healthy male adults. Calcif Tissue Int 73 (2003) 356-360
28. Verrotti A., Greco R., Latini G., Morgese G., and Chiarelli F. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 43 (2002) 1488-1492
29. Christiansen C., Rodbro P., and Tjellesen L. Pathophysiology behind anticonvulsant osteomalacia. Acta Neurol Scand 94 (1983) 21-28
30. Fitzpatrick L.A. Pathophysiology of bone loss in patients receiving anticonvulsant therapy. Epilepsy Behav 5 (2004) S3-S15
31. Hahn T.J., Hendin B.A., Scharp C.R., and Haddad Jr. J.G. Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults. N Engl J Med 287 (1972) 900-904
32. Feldkamp J., Becker A., Witte O.W., Scharff D., and Scherbaum W.A. Long-term anticonvulsant therapy leads to low bone mineral density: evidence for direct effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp Clin Endocrinol Diabetes 108 (2000) 37-43
33. Pento J.T., Glick S.M., and Kagan A. Diphenylhydantoin inhibition of calcitonin secretion in the pig. Endocrinology 92 (1973) 330-333
34. Kruse K., Suss A., Busse M., and Schneider P. Monomeric serum calcitonin and bone turnover during anticonvulsant treatment and in congenital hypothroidism. J Pediatr 111 (1987) 57-63
35. Vernillo A.T., Rifkin B.R., and Hauschka P.V. Phenytoin affects osteocalcin secretion from osteoblastic rat osteosarcoma 17/2.8 cells in culture. Bone 11 (1990) 309-312
36. Pack A.M., Olarte L.S., Morrell M.J., et al. Bone mineral density in an outpatient population receiving enzyme-inducing antiepileptic drugs. Epilepsy Behav 4 (2003) 169-174
37. Pothiwala P., Evans E.M., and Chapman-Novakofski K.M. Ethnic variation in risk for osteoporosis among women: a review of biological and behavioral factors. J Womens Health (Larchmt) 15 (2006) 709-719
38. Barrett-Connor E., Siris E.S., Wehren L.E., et al. Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res 20 (2005) 185-194
39. Pack A.M., and Morrell M.J. Adverse effects of antiepileptic drug on bone structure: epidemiology, mechanisms and therapeutic implications. CNS Drugs 15 (2001) 633-642
40. Drezner M.K. Treatment of anticonvulsant drug-induced bone disease. Epilepsy Behav 5 (2004) S41-S47